TOP
Nav Bar
  1. General Info
  2. Effects Info
  3. Reference
Drug Details
01. General Information
Name Panitumumab
Drug Type Antibody
TTD ID D0HU9H
Toxicity Organism Test Type Route(Dose)
Structure 2D-img
Download
2D MOL 3D MOL
02. Combinatorial Therapeutic Effect(s)
Synergistic Effect
Hide/Show
Decreasing Drug Toxicity
Hide/Show
Combination Pair ID: 333
Ref_1
Pair Name Schisandrin B, Panitumumab
Partner Name Schisandrin B
Disease Info [ICD-11: 2B91] Colorectal cancer Investigative
Biological Phenomena Induction-->Autophagy
Gene Regulation Down-regulation Expression BCL2 hsa596
Down-regulation Expression BECN1 hsa8678
Up-regulation Activity CASP3 hsa836
Down-regulation Expression MAP1LC3B hsa81631
In Vitro Model Caco-2 Colon adenocarcinoma Homo sapiens (Human) CVCL_0025
HCT 116 Colon carcinoma Homo sapiens (Human) CVCL_0291
HT-29 Colon adenocarcinoma Homo sapiens (Human) CVCL_0320
Result This novel combination therapy against CRC, allows the reduction of panitumumab dose to guard against its adverse effects.
03. Reference
No. Title Href
1 The potential effect of Schisandrin-B combination with panitumumab in wild-type and mutant colorectal cancer cell lines: Role of apoptosis and autophagy. J Biochem Mol Toxicol. 2023 May;37(5):e23324. doi: 10.1002/jbt.23324. Click
It has been 26570 visits since 2024.08
If you find any error in data or bug in web service, please kindly report it to Dr. Zhang
TOP